Bioamber Inc (NYSE:BIOA) has earned a consensus broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has given a strong buy rating to the company.

Brokers have set a twelve-month consensus price target of $6.50 for the company and are forecasting that the company will post ($0.18) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Bioamber an industry rank of 151 out of 265 based on the ratings given to its competitors.

BIOA has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Bioamber in a research report on Wednesday, November 8th. Cowen reiterated a “hold” rating and set a $1.00 price objective on shares of Bioamber in a research report on Friday, November 10th. Zacks Investment Research upgraded shares of Bioamber from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, ValuEngine cut shares of Bioamber from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st.

Bioamber (NYSE BIOA) opened at $0.45 on Friday. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.08 and a quick ratio of 0.75. The stock has a market cap of $23.19, a P/E ratio of -0.64 and a beta of 2.65. Bioamber has a 12-month low of $0.32 and a 12-month high of $5.93.

Large investors have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its stake in shares of Bioamber by 336.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 41,701 shares during the period. Vanguard Group Inc. boosted its stake in shares of Bioamber by 9.9% during the 2nd quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock valued at $780,000 after buying an additional 27,278 shares during the period. FMR LLC boosted its stake in shares of Bioamber by 1.9% during the 2nd quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock valued at $3,495,000 after buying an additional 25,000 shares during the period. Finally, Robecosam AG boosted its stake in shares of Bioamber by 82.9% during the 3rd quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock valued at $741,000 after buying an additional 670,000 shares during the period. 29.97% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Set $6.50 Price Target for Bioamber Inc (BIOA)” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/12/zacks-analysts-set-6-50-price-target-for-bioamber-inc-bioa.html.

About Bioamber

BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.

Get a free copy of the Zacks research report on Bioamber (BIOA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.